Browse > Article

The Effects of MeOH Extract of Hopea chinensis (Merr.) Hand.-Mazz. on the Metabolism of Amyloid Precursor Protein in Neuroblastoma Cells  

Chandra, Shrestha Abinash (College of Pharmacy, Woosuk University)
Kim, Ju Eun (College of Pharmacy, Woosuk University)
Ham, Ha Neul (College of Pharmacy, Woosuk University)
Jo, Youn Jeong (College of Pharmacy, Woosuk University)
Bach, Tran The (Institute of Ecology and Biological Resources (IEBR), Vietnam Academy of Science and Technology (VAST))
Eum, Sang Mi (Korea Research Institute of Bioscience & Biotechnology (KRIBB))
Leem, Jae Yoon (College of Pharmacy, Woosuk University)
Publication Information
Korean Journal of Pharmacognosy / v.49, no.2, 2018 , pp. 182-187 More about this Journal
Abstract
Many plant derived phytochemicals have been considered as the main therapeutic strategy against Alzheimer's disease (AD). AD is a progressive neurodegenerative disorder, and the most predominant cause of dementia in the elderly. Cholinergic deficit, senile plaque/${\beta}$-amyloid ($A{\beta}$) peptide deposition and oxidative stress have been identified as three main pathogenic pathways which contribute to the progression of AD. We screened many different plant species for their effective use in both modern and traditional system of medicines. In this study, we tested that MeOH extract of the stem bark of Hopea chinensis (Merr.) Hand.-Mazz. (HCM) affects on the processing of Amyloid precursor portein (APP) from the APPswe over-expressing Neuro2a cell line. We showed that HCM reduced the secretion level of $A{\beta}42$ and $A{\beta}40$ in a dose dependent manner. We found that HCM increased over 1.5 folds of the secretion level of $sAPP{\alpha}$, a metabolite of ${\alpha}$-secretase. Furthermore, we found that HCM inhibited acetylcholinesterase activity in vitro. We suggest that the stem bark of Hopea chinensis may be a useful source to develop a therapeutics for AD.
Keywords
Hopea chinensis (Merr.) Hand.-Mazz.; Alzheimer's disease; ${\beta}$-amyloid; Acetylcholinesterase; APPswe; $sAPP{\alpha}$;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Harun A., Muhammad J. J. R., Lim S. M, Bakar A. M. A., Cole A. L. J. and Ramasamy K. (2011) BACE1 inhibitory activity of fungal endophytic extracts from Malaysian medicinal plants. BMC Complement Altern. Med. 11: 79.   DOI
2 Selkoe, D. J. (1998) The cell biology of beta-amyloid precursor protein and presenilin in Alzheimer's disease. Trends Cell Biol. 8: 447-453.   DOI
3 Strittmatter, W. J., Weisgraber, K. H. Huang, D. Y., Dong, L. M., Salvesen, G. S., Pericak-Vance, M., Schmechel, D., Saunders, A. M., Goldgaber, D. and Roses, A. D. (1993) Binding of human apolipoprotein E to synthetic amyloid beta peptide isoform-specific effects and implications for late-onset Alzheimer disease. Proc. Natl. Acad. Sci. USA 90: 8098-8102.   DOI
4 Leem, J. Y., Saura, C. A., Pietrzik, C., Christianson, J., Wanamaker, C., King, L. T., Veselits, M. L., Tomita, T., Gasparini, L., Iwatsubo, T., Xu, H., Green, W. N., Koo, E. H. and Thinakaran, G. (2002) A role for presenilin 1 in regulating the delivery of amyloid precursor protein to the cell surface. Neurobiol. Dis. 11: 64-82.   DOI
5 Fu, H., Dou, J., Li, W., Cui, W., Mak, S., Hu, Q., Luo, J., Lam, C. S., Pang, Y., Youdim, M. B. and Han, Y. (2009) Promising multifunctional anti-Alzheimer's dimer bis(7)-Cognitin acting as an activator of protein kinase C regulates activities of alpha-secretase and BACE-1 concurrently. Eur. J. Pharmacol. 623: 14-21.   DOI
6 Sugimoto, H. (2001) Donepezil hydrochloride. a treatment drug for Alzheimer's disease. Chem. Rec. 1: 63-73.   DOI
7 Cai, H., Wang, Y., McCarthy, D., Wen, H., Borchelt, D. R., Price, D. L. and Wong, P. C. (2001) BACE1 is the major ${\beta}$-secretase for generation of $A{\beta}$ peptides by neurons. Nature Neurosci. 4: 233-234.   DOI
8 Corder, E. H., Saunders, A. M., Strittmatter, W. J., Schmechel, D. E., Gaskell, P. C., Small, G. W., Roses, A .D., Haines, J. L. and Pericak-Vance, M. A. (1993) Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 261: 921-923.   DOI
9 Vassar, R., Bennett, B. D., Babu-Khan, S., Kahn, S., Mendiaz, E. A., Denis, P., Teplow, D. B., Ross, S., Amarante, P., Loeloff, R., Luo, Y., Fisher, S., Fuller, J., Edenson, S., Lile, J., Jarosinski, M. A., Biere, A. L., Curran, E., Burgess, T., Louis, J. C., Collins, F., Treanor, J., Rogers, G. and Citron, M. (1999) ${\beta}$-Secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. Science 286: 735-741.   DOI
10 Selkoe, D. J. (1999) Translating cell biology into therapeutic advances in Alzheimer's disease. Nature 399: 23-31.   DOI
11 통계청 자료(http://kosis.kr/statHtml/statHtml.do?orgId=101&tblId=DT_1B35001)
12 1. Yan, T., Wang, T., Wei, W., Jiang, N., Qin, Y. H., Tan, R. X. and Ge, H. M. (2012) Polyphenolic acetylcholinesterase inhibitors from Hopea chinensis. Planta Med. 78: 1015-1019.   DOI
13 Zarotsky, V., Sramek, J. J. and Cutler, N. R. (2003) Galantamine hydrobromide. an agent for Alzheimer's disease. Am. J. Health Syst. Pharm. 60: 446-452.
14 Jann, M. W. (2000) Rivastigmine, a new-generation cholinesterase inhibitor for the treatment of Alzheimer's disease. Pharmacotherapy 20: 1-12.   DOI
15 Ge, H. M., Zhu, C. H., Shi, D. H., Zhang, L. D., Xie, D. Q., Yang, J., Ng, S. W. and Tan RX. (2008) Hoeahainol A: an acetylcholinesterase inhibitor from Hopea hainanensis. Chem. Eur. J. 14: 376-381.   DOI
16 Ge, H. M., Yang, W. H., Shen, Y., Jiang, N., Guo, Z.K., Luo. Q., Xu, Q., Ma, J. and Tan, R. X. (2010) Immunosuppressive resveratrol aneuploids from Hopea chinensis. Chemistry. 16: 6338-6345.   DOI
17 Wang, R., Sweeney, D., Gandy, S. E. and Sissodia, S. S. (1996) The profile of soluble amyloid ${\beta}$ protein in cultured cell media. J. Biol. Chem. 271: 31894-31902.   DOI
18 Citron, M., Westaway, D., Xia, W., Carlson, G., Diehl, T., Levesque, G., Johnson-Wood, K., Lee, M., Seubert, P., Davis, A., Kholodenko, D., Motter, R., Sherrington, R., Perry, B., Yao, H., Strome, R., Lieberburg, I., Rommens, J., Kim, S., Schenk, D., Fraser, P., St George Hyslop, P. and Selkoe. D. J. (1997) Mutant presenilins of Alzheimer's disease increase production of 42-residue amyloid beta-protein in both transfected cells and transgenic mice. Nat. Med. 3: 67-72.   DOI
19 Morris, J. C. (1996) Classification of dementia and Alzheimer's disease. Acta Neurol. Scand. 165: 41-50.
20 Nunan, J. and Small, D. H. (2000) Regulation of APP cleavage by alpha-, beta- and gamma-secretases. FEBS Lett. 483: 6-10.   DOI
21 Kuo, Y. M., Emmerling, M. R., Vigo-Pelfrey, C., Kasunic, T. C., Kirkpatrick, J. B., Murdoch, G. H., Ball, M. J. and Roher, A. E. (1996) Water-soluble Abeta (N-40, N-42) oligomers in normal and Alzheimer disease brains. J. Biol. Chem. 271: 4077-4081.   DOI
22 Takahashi, Y., Hayashi, I., Tominari, Y., Rikimaru, K., Morohashi, Y., Kan, T., Natsugari, H., Fukuyama, T., Tomita, T. and Iwatsubo, T. (2003) Sulindac sulfide is a noncompetitive gamma-secretase inhibitor that preferentially reduces Abeta 42 generation. J. Biol. Chem. 278: 18664-18670.   DOI
23 Uchida N, Takasaki K, Sakata Y, Nogami A, Oishi H, Watanabe T, Shindo T, Egashira N, Kubota K, Katsurabayashi S, Mishima K, Fujiwara M, Nishimura R, Iwasaki K. (2013) Cholinergic involvement and synaptic dynamin 1 expression in Yokukansan-mediated improvement of spatial memory in a rat model of early Alzheimer's disease. Phytother. Res. 27: 966-972.   DOI
24 Obregon, D., Hou, H., Deng, J., Giunta, B., Tian, J., Darlington, D., Shahaduzzaman, M., Zhu, Y., Mori, T., Mattson, MP. and Tan, J. (2012) Soluble amyloid precursor protein-${\alpha}$ modulates ${\beta}$-secretase activity and amyloid-${\beta}$ generation. Nat. Commun. 3: 777.   DOI
25 Skovronsky, D. M., Moore, D. B., Milla, M. E., Doms, R. W. and Lee, V. M. (2000) Protein kinase C-dependent alpha-secretase competes with beta-secretase for cleavage of amyloid-beta precursor protein in the trans-golgi network. J. Biol. Chem. 275: 2568-2575.   DOI
26 Tung, J. S., Davis, D. L., Anderson, J. P., Walker, D. E., Mamo, S., Jewett, N., Hom, R. K., Sinha, S. and Thorsett, E. D., John, V. (2002) Design of substrate-based inhibitors of human beta-secretase. J. Med. Chem. 45: 259-262.   DOI
27 Iqbal, K., Sisodia, S. S. and Winblad, B. (2001) Alzheimer's disease. Advances in etiology, pathogenesis and therapeutics. John Wiley & Sons, Ltd.
28 Li, N., Zhou, L., Li, W., Liu, Y., Wang, J. and He, P. (2015) Protective effects of ginsenosides Rg1 and Rb1 on an Alzheimer's disease mouse model: A metabolomics study. J. Chromatogr. B Analyt.. Technol. Biomed. Life Sci. 985: 54-61.   DOI
29 Hardy, J. and Selkoe, D. J. (2002) The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297: 353-356.   DOI
30 Steiner, H., Winkler, E., Edbauer, D., Prokop, S., Basset, G., Yamasaki, A., Kostka, M. and Haass, C. (2002) PEN-2 is an integral component of the ${\gamma}$-secretase complex required for coordinated expression of presenilin and nicastrin. J. Biol. Chem. 277: 39062-39061.   DOI
31 Sambamurti, K., Hardy, J., Refolo L. M. and Lahiri, D. K. (2002) Targeting APP metabolism for the treatment of Alzheimer's disease. Drug Dev. Res. 56: 211-227.   DOI